Abiopharma

🔍 FMR LLC (Executive)

Company: Avalyn Pharma Inc. (AVLN)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 727,585 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | shares_owned_after: 727,585.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 80,291 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | shares_owned_after: 807,876.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 872,868 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | shares_owned_after: 1,680,744.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 225,843 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | shares_owned_after: 1,906,587.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 377,948 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | shares_owned_after: 2,284,535.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 727,585 shares of Series A Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 80,291 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 872,868 shares of Series C-1 Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 225,843 shares of Series C-2 Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 377,948 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-01 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

Footnotes:

• F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
• REMARKS: Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager.